Intellectual Property India Publishes Patent Application for 'Combination Therapies With Bi-Specific Anti-Egfr/C-Met Antibodies And Anti-Pd-1 Antibodies' Filed by Janssen Biotech, Inc.

MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202517097781 A) filed by Janssen Biotech, Inc., Horsham, U.S.A., on Oct. 10, for 'combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies.'

Inventor(s) include Curtin, Joshua; and Baig, Mahadi.

The application for the patent was published on Nov. 21, under issue no. 47/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to combination therapies for modulating the tumor microenvironment and enhancing immune cell infiltration into the tumor microenvironment with bispecific anti-EGFR/c-Met antibodies in combination with PD- (L)1 axis inhibitors. The invention also relates to combination therapies for inhibition of both EGFR and MET signaling pathways in a tumor cell, and targeting of EGFR and MET expressing tumor cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."

The patent application was internationally filed on Mar. 12, 2024, under International application No.PCT/IB2024/052394.

Disclaimer: Curated by HT Syndication.